Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 6Genitourinary 2Thoracic 1Sarcoma 1Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Dermatologic 1CNS 1

Conditions

Sarcoma, Synovial 2Sarcoma, Ewing 2Rhabdomyosarcoma 2Osteosarcoma 2Stomach Neoplasms 1Sarcoma 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neuroblastoma 1Multiple Myeloma 1Mesothelioma 1Melanoma 1Lymphoma 1Lung Neoplasms 1Leukemia, Myeloid 1Gliosarcoma 1Glioma 1Glioblastoma 1Esophageal Neoplasms 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Burkitt Lymphoma 1Brain Neoplasms 1

Interventions

Gemcitabine 9pembrolizumab 7Irinotecan 5Docetaxel 4Cisplatin 4Carboplatin 4Capecitabine 4Albumin-Bound Paclitaxel 4Paclitaxel 3Oxaliplatin 3Leucovorin 3Cyclophosphamide 3Cetuximab 3130-nm albumin-bound paclitaxel 3pazopanib 2palbociclib 2liposomal doxorubicin 2entrectinib 2alectinib 2Vinorelbine 2Trastuzumab 2Taxes 2Radiosurgery 2Oncolytic Virotherapy 2Observation 2Ipilimumab 2Fluorouracil 2Fluorodeoxyglucose F18 2Filgrastim 2Erlotinib Hydrochloride 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × Immunotherapy, Adoptive × Sarcoma × Clear all
NCT03638206 2019-12-11

Autologous CAR-T/TCR-T Cell Immunotherapy for Malignancies

Shenzhen BinDeBio Ltd.

Phase 1/2 Unknown
73 enrolled
CNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidOther hematologic neoplasmOther solid neoplasmPlasma cellSarcomaThoracic

Burkitt Lymphoma, Carcinoma, Renal Cell, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Leukemia, Myeloid, Lung Neoplasms, Lymphoma, Melanoma, Mesothelioma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Sarcoma, Synovial, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡